Dolomite (CAS 16389-88-1) Industry Report 2025: Global and Regional Market Trends 2019-2024 and Forecasts 2025-2029 - Manufacturers, Market Prices, Patents, Down-stream Industries
DUBLIN--(BUSINESS WIRE)--Apr 17, 2025--
The 'Dolomite (CAS 16389-88-1) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
This report on Dolomite provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth study serves as a vital resource for understanding the Dolomite market landscape and its growth potential worldwide.
It explores various applications and examines manufacturing methods, supported by an analysis of relevant patents. The global market analysis covers constraints, drivers, and opportunities from 2019 to 2024, supply and demand dynamics, suppliers and regional overviews across Europe, Asia, North America, and other regions.
The report forecasts future trends and supply-demand scenarios up to 2029, with detailed market predictions by region. Additionally, it analyzes market prices across different regions and evaluates the end-use sectors for Dolomite.
The Dolomite global market report covers the following key points:
Key questions answered in the report:
Key Topics Covered:
1. DOLOMITE
1.1. General information, synonyms
1.2. Composition, chemical structure
1.3. Safety information
1.4. Hazards identification
1.5. Handling and storage
1.6. Toxicological & ecological information
1.7. Transport information
2. DOLOMITE APPLICATIONS
3. DOLOMITE MANUFACTURING METHODS
4. DOLOMITE PATENTS
5. DOLOMITE WORLD MARKET ANALYSIS
5.1. Dolomite market constraints, drivers and opportunities in 2019-2024
5.2. Dolomite supply/demand in 2019-2024
5.3. Dolomite market overview by region - Europe, Asia, North America, etc.
6. MANUFACTURERS OF DOLOMITE
6.1. Dolomite manufacturers in Europe
6.2. Dolomite manufacturers in Asia
6.3. Dolomite manufacturers in North America
6.4. Dolomite manufacturers in RoW
7. SUPPLIERS OF DOLOMITE
7.1. Dolomite suppliers in Europe
7.2. Dolomite suppliers in Asia
7.3. Dolomite suppliers in North America
7.4. Dolomite suppliers in RoW
8. DOLOMITE WORLD MARKET FORECAST
8.1. Future trends in global Dolomite market
8.2. Dolomite supply/demand forecast to 2029
8.3. Dolomite market forecast to 2029 by region (Europe, Asia, North America, etc.)
9. DOLOMITE MARKET PRICES
9.1. Dolomite prices in Europe
9.2. Dolomite prices in Asia
9.3. Dolomite prices in North America
9.4. Dolomite prices in RoW
10. DOLOMITE END-USE SECTOR
For more information about this report visit https://www.researchandmarkets.com/r/6lv10n
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250417228892/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: MINING/MINERALS NATURAL RESOURCES
SOURCE: Research and Markets
Copyright Business Wire 2025.
PUB: 04/17/2025 09:28 AM/DISC: 04/17/2025 09:28 AM
http://www.businesswire.com/news/home/20250417228892/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
$13.16 Bn Human Growth Hormone (HGH) Market Trends and Forecasts, 2020-2024 & 2025-2030: Strategic R&D Initiatives, Regulatory Approvals, and Collaborations Shaping the Landscape
The Human Growth Hormone market offers significant opportunities driven by the rise in growth hormone deficiencies and aging populations seeking HGH therapy. The demand is boosted by potential anti-aging and wellness benefits, with biosimilars presenting a cost-effective alternative. Key challenges include high costs and ethical issues. Human Growth Hormone (HGH) Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Human Growth Hormone (HGH) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to Human Growth Hormone (HGH) Market was valued at USD 6.21 Billion in 2024, and is expected to reach USD 13.16 Billion by 2030, rising at a CAGR of 13.29% This rapidly evolving sector within the pharmaceutical and biotechnology industry centers on the use of somatotropin - a crucial hormone produced by the pituitary gland - to support growth, development, and metabolic functions. Key growth drivers include the rising prevalence of growth hormone deficiencies (GHD), especially among children, and increased interest in HGH therapy among the aging population to address age-related hormonal decline. In addition to its approved medical applications, HGH is being explored for its potential anti-aging and wellness benefits, further expanding its demand. The market features a wide range of products, including recombinant human growth hormone (rhGH) and biosimilars, with injectable formulations dominating the segment. Strategic R&D initiatives, regulatory approvals, and collaborations among pharmaceutical companies are shaping the market's competitive landscape. However, accessibility issues and high treatment costs remain challenges, alongside ethical concerns about off-label use for enhancement Market Drivers Increasing Prevalence of Growth Hormone Deficiency (GHD)The growing incidence of Growth Hormone Deficiency (GHD) remains a primary catalyst for the Human Growth Hormone (HGH) market globally. GHD, caused by inadequate hormone secretion from the pituitary gland, significantly affects growth, especially in children, and impacts overall health in adults. Current estimates suggest that GHD occurs in 1 out of every 4,000 to 10,000 live births, with a substantial number of adult-onset cases recorded annually. Greater awareness and improved diagnostic tools have enabled earlier detection and intervention, enhancing patient factors include poor nutrition, increased stress, genetic disorders, and medical conditions involving the hypothalamic-pituitary axis. As access to healthcare broadens, more individuals are seeking evaluation and treatment for growth-related disorders, spurring pharmaceutical companies to develop long-acting therapies and improve patient compliance. This growing patient population continues to drive demand for HGH treatment solutions Market Challenges High CostCost remains a significant barrier in the Global Human Growth Hormone (HGH) Market. The complex production process of recombinant human growth hormone (rhGH), involving high-end biotechnological methods and rigorous quality standards, contributes to elevated prices. The long duration of therapy, often lasting several years, further increases the financial burden on patients and healthcare systems. Limited insurance coverage in certain regions and insufficient public health resources exacerbate access issues. As a result, many patients are unable to afford or maintain treatment, especially in lower-income markets. Addressing affordability through cost-effective production and pricing strategies is essential to broaden access to life-enhancing HGH Market Trends BiosimilarsThe growing presence of biosimilars is a transformative trend in the Global Human Growth Hormone (HGH) Market. These are biologic products designed to closely resemble original rhGH therapies in terms of safety, efficacy, and quality, but at a more accessible price point. Biosimilars undergo stringent regulatory scrutiny and clinical testing to ensure comparable performance to reference introduction promotes market competition, helping to reduce treatment costs and improve patient access. As biosimilar adoption expands, particularly in cost-sensitive regions, their role in the market is increasing. Nevertheless, regulatory approval processes, interchangeability protocols, and manufacturing consistency remain key considerations. Overall, biosimilars represent a promising path toward greater affordability and availability of HGH treatments. Key Attributes: Report Attribute Details No. of Pages 185 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $6.21 Billion Forecasted Market Value (USD) by 2030 $13.16 Billion Compound Annual Growth Rate 13.2% Regions Covered Global Report Scope: Key Market Players Novo Nordisk A/S Eli Lilly and Company Pfizer, Inc. Sandoz International GmbH (Novartis AG) Genentech, Inc. (Roche) Merck KGaA Ferring Pharmaceuticals Ipsen Pharma Teva Pharmaceutical Industries, Ltd. Human Growth Hormone (HGH) Market, By Product: Long Acting Others Human Growth Hormone (HGH) Market, By Application: Growth Hormone (GH) Deficiency Turner Syndrome Idiopathic Short Stature Prader-Willi Syndrome Small for Gestational Age Other Human Growth Hormone (HGH) Market, By Distribution Channel: Hospital Pharmacy Retail Pharmacy Online Pharmacy Specialty Pharmacy Human Growth Hormone (HGH) Market, By Region: North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Growth Hormone (HGH) Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
34 minutes ago
- Yahoo
SailPoint Strengthens South American Presence with AWS-Based SaaS Instance in Brazil
AUSTIN, Texas & SíO PAULO, Brazil, June 10, 2025--(BUSINESS WIRE)--SailPoint, Inc. (NASDAQ: SAIL), a leader in unified identity security, today announced the June launch of its first Software-as-a-Service (SaaS) instance in South America, hosted on Amazon Web Services (AWS) in Brazil. This launch highlights the strategic expansion of SailPoint's global footprint and demand for identity security solutions around the world. The Brazil SaaS instance will support increasing demand for SailPoint Identity Security Cloud regionally, addressing expectations around data sovereignty, regulatory compliance and security. The new instance will enable organizations in highly regulated industries—such as finance, healthcare and government—to unlock the business value of cloud adoption and leverage SailPoint's industry-leading identity security platform, SailPoint Atlas, locally. "Launching a SaaS instance in Brazil is more than just adding infrastructure—it's about empowering local enterprises with identity security solutions that are secure, scalable and tailored to regional requirements," said Gary Nafus, Chief Commercial Officer at SailPoint. "From our vantage point, organizations in South America are accelerating their digital transformation journeys, and we believe our regional SaaS offering will empower them to do so with confidence—improving security posture, supporting compliance efforts, and reducing operational complexity." Built as a multi-tenant SaaS environment on AWS, the Brazil instance is fully isolated from other AWS regions, designed to prevent customer data from being replicated or stored outside the region. This announcement underscores SailPoint's long-term vision to be the identity security partner of choice for global enterprises. By expanding its SaaS footprint into South America, SailPoint continues to enable organizations to scale securely, simplify compliance, and defend against today's evolving identity threats. For more information about SailPoint Identity Security Cloud visit: About SailPoint, Inc. At SailPoint, we believe enterprise security must start with identity at the foundation. Today's enterprise runs on a diverse workforce of not just human but also digital identities—and securing them all is critical. Through the lens of identity, SailPoint empowers organizations to seamlessly manage and secure access to applications and data at speed and scale. Our unified, intelligent, and extensible platform delivers identity-first security, helping enterprises defend against dynamic threats while driving productivity and transformation. Trusted by many of the world's most complex organizations, SailPoint secures the modern enterprise. View source version on Contacts Media Relations for SailPoint Samantha PersonSenior Manager, PR & Corporate
Business Wire
2 hours ago
- Business Wire
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Elevation Oncology, Inc. (NasdaqCM: ELEV) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Elevation will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. Please note that the transaction is structured as a tender offer, such that time may be of the essence. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
